In addition, antibodies against amyloid (passive immunization); inhibitors of glycogen synthase kinase (GSK)3β, which phosphorylates tau; and nonsteroidal anti-inflammatory drugs (NSAIDs) targeting neuroinflammation can be used as AD treatment [13,17]. The gene discussed is MAPT; the disease is Alzheimer disease.